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clinically significant differences in formulation, dosages, 
efficacy, or safety. In this review, we explore the differences 
between biosimilars and intended copies and describe key 
concepts related to biosimilars. Familiarity with these top-
ics may facilitate decision making about the appropriate 
use of biosimilars for patients with rheumatic and muscu-
loskeletal diseases.
Keywords Biosimilar · Intended copy · Biologic · 
Pharmacovigilance · Regulatory
Introduction
A biologic medicine is a large molecule derived from living 
cells and typically produced by recombinant DNA, hybri-
doma, or other technologies [1]. Biologics are used in the 
treatment, diagnosis, or prevention of several non-commu-
nicable and some communicable diseases and conditions 
and include hormones, small proteins, vaccines, monoclo-
nal antibodies, and fusion proteins [2]. The introduction of 
biologics (e.g., etanercept, adalimumab, infliximab, rituxi-
mab, abatacept, and tocilizumab) revolutionized treatment 
algorithms in patients with rheumatic and musculoskeletal 
diseases (RMDs), including chronic autoimmune inflam-
matory diseases, such as rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, and juvenile idiopathic 
arthritis [3–7]. These conditions incur high individual, soci-
etal, and health care system costs [5] and have a significant 
effect on patient health-related quality of life and risk of 
comorbidities [8]. Achieving remission in the clinical and 
functional domains of rheumatic diseases has become a 
feasible target with biologic therapies [4], and treatment 
should be focused on achieving this target or, at a mini-
mum, low disease activity in every patient [5]. However, 
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logic in terms of safety and efficacy and to have no clini-
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the escalating burden of chronic diseases, including RMDs, 
and worldwide shortage of rheumatologists amid cost con-
straints and national health care system heterogeneity con-
stitute barriers that have resulted in limited access to bio-
logics. Today, access to these highly effective treatments 
for rheumatic diseases remains an unmet medical need for 
many people around the world [9].
As patents expire for existing licensed (referred to as 
reference or originator) biologics, biosimilar products can 
be approved by regulatory authorities, and thus enter clini-
cal use. Biopharmaceutical manufacturers around the world 
are developing versions of the existing licensed biologics; 
however, not all of these versions have evidence to dem-
onstrate comparable physiochemical and functional proper-
ties, efficacy, and safety profiles as defined by regulatory 
authorities and recommended by the World Health Organi-
zation (WHO) [10]. This is of particular interest to rheuma-
tologists as many biopharmaceutical manufacturers world-
wide are developing follow-on biologics of products used 
in the treatment for rheumatologic conditions, including 
adalimumab, etanercept, infliximab, and rituximab.
Biosimilars are highly similar copies of originator bio-
logics approved through defined and stringent regula-
tory processes after having undergone rigorous analytical, 
immunogenicity, non-clinical, and clinical comparative 
evaluations. Non-comparable biotherapeutic products (also 
known as “intended copies” or “biomimics”) are copies of 
originator biologics that have not undergone such evalua-
tions and have not met strict regulatory requirements such 
as those of the WHO, European Medicines Agency (EMA) 
[11], or US Food and Drug Administration (FDA) [12]. In 
this review, we explore the differences between biosimilars 
and intended copies and discuss the unique developmental 
processes used for biologics, including biosimilars. We also 
summarize the regulatory standards for the development and 
approval of biosimilars in various regions of the world and 
examine current differences between regions. Further, we 
review several key areas of interest for biosimilars, includ-
ing naming, pharmacovigilance, and risk management.
Biosimilars
The term “biosimilar” is a regulatory definition that refers 
to a biologic product that is developed to be highly simi-
lar to, and treat the same conditions as, an existing licensed 
or approved biologic product. A biosimilar, as defined by 
the WHO, is a “biotherapeutic product which is similar in 
terms of quality, safety, and efficacy to an already licensed 
reference biotherapeutic product,” in which similarity 
is defined as the “absence of a relevant difference in the 
parameter of interest” [10]. Biosimilars are highly similar 
versions of marketed biologic medicines and are supported 
by appropriate analytical and immunogenicity testing and 
non-clinical and clinical trials to demonstrate that they 
are sufficiently “similar” in quality, efficacy, and safety to 
their reference (originator) biologics. Unlike conventional 
medicines, also called “small molecules,” biologic drugs 
are large, structurally complex molecules. Because they 
are biologics, biosimilars should not be viewed as generic 
medicines, and unlike small-molecule generics, they cannot 
be manufactured to be identical to the originator biologic. 
Manufacturing of biosimilars is generally more complex 
than manufacturing generics. In addition, the regulatory 
process for biosimilar approval is very different from the 
approval process for small-molecule generic medicines, 
and it is precisely the regulatory process that defines these 
categories. Although both biosimilars and generics require 
pharmacokinetic bioequivalence studies, biosimilars must 
demonstrate high similarity to the originator product [10–
12], whereas small-molecule generics must show proof of 
quality (i.e., identical chemical structure).
Non‑comparable biotherapeutic products 
(intended copies)
Prior to the implementation of science-based regulatory 
pathways for the approval of biosimilars, copies of origi-
nator biologic products were introduced in some countries. 
The basis for approval of these copies has not been clear 
as they lack comparative studies to an appropriate ref-
erence product. Most, if not all of these products, can be 
considered as non-comparable biotherapeutic products, or 
intended copies (sometimes referred to as biomimics [13, 
14]). Intended copies of biologics can be defined as cop-
ies of already licensed biologic products that have not met 
the requirements of the WHO, EMA, or FDA to establish 
biosimilarity [10–12]. In other words, intended copies are 
products for which the manufacturer intended to make a 
copy but did not follow a comparative development path-
way with the reference medicine. Their similarity exercises 
may be incomplete, analytical evidence may be insufficient, 
or they may either lack clinical trials or were studied only 
in limited or methodologically inadequate clinical trials 
[15, 16]. Often, intended copy products are developed inde-
pendently and are not directly compared against a licensed 
biologic product, and they may or may not be compared 
clinically. Thus, the data available to assess intended cop-
ies do not provide adequate comparable efficacy and safety 
to the licensed product. These products may have clinically 
significant differences in formulation, dosages, efficacy, or 
safety from what is required for a biosimilar [17]. There is 
no clear evidence that intended copies have efficacy and 
safety similar to the originator biologic or a biosimilar 
owing to the absence of rigorous clinical testing.
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It is important that rheumatologists distinguish between 
intended copies and biosimilars. In some countries with-
out biosimilar regulations or with non-stringent regula-
tory environments, intended copies are being approved as 
generic drugs, which allows pharmaceutical manufacturers 
to make and sell copies of the reference drug without estab-
lishing proper biosimilarity between these products and the 
reference products [18, 19]. Furthermore, in some coun-
tries with less stringent regulation, copies of biologics have 
been marketed without clinical trials [20] or based on stud-
ies that were limited in scope, size, or scientific rigor [17]. 
For example, intended copies of etanercept are marketed 
in several countries, including China, India, Colombia, 
and Mexico. Additionally, an intended copy of rituximab 
is manufactured in India and marketed in India and several 
Latin American countries [19, 21] despite the apparent lack 
of a comparative clinical trial with the originator biologic 
in patients with RMDs. Because data are lacking to estab-
lish that these products are highly similar to the origina-
tor biologic, they cannot be considered to be biosimilars 
[17]. Compounding this problem is the challenge of find-
ing detailed study methods and results for these copies in 
the public domain (e.g., clinical trial registries, published 
congress abstracts, and indexed publications) that would 
permit independent evaluation of products. This is in sharp 
contrast to the monoclonal antibody CT-P13 (Remsima™/
Inflectra™), approved by EMA and under review by the 
FDA as a biosimilar to reference infliximab (Remicade®). 
In analytical studies, CT-P13 demonstrated an identical 
amino acid sequence as the originator infliximab, produc-
tion on the same type of cell line, comparable pharmacody-
namics, including binding activity to human tumor necrosis 
factor alpha (TNFα), and cytotoxic activities against a cell 
line expressing transmembrane human TNFα [22, 23]. This 
detailed in vitro characterization was followed by clinical 
evaluations that demonstrated comparable efficacy, safety, 
and immunogenicity to originator, infliximab [22, 24]. 
Although in Europe these findings were not part of the 
product label, the study methods and results were made 
available through European public assessment reports 
(EPAR) and peer-reviewed publications [22–24].
Manufacturing biologics
In order to appreciate the need for science-based regulatory 
pathways for approval of biosimilars and the differences 
between biosimilars and intended copies, it is important 
to understand the molecular complexity of biologics and 
how they are manufactured. Important differences exist 
in the molecular complexity and manufacturing processes 
between small-molecule drugs and biologics. As their 
name implies, small-molecule drugs are small in size and 
have less complex chemical structures. The chemical struc-
ture of a generic small-molecule drug can be characterized 
using current technology to guarantee that it is identical to 
the active drug in the reference product [25]. In contrast, 
biologics are proteins typically developed using living sys-
tems, such as bacteria, yeast, or mammalian cells, and are 
much larger and more complex than small-molecule drugs 
[26]. Protein structure and manufacturing processes to pro-
duce them have been discussed extensively in the literature 
[27–32] and will not be provided in detail in this manu-
script. The pharmacologic action of monoclonal antibod-
ies used to treat RMDs will depend not only on the amino 
acid sequence (primary structure) [25, 33], but also on sec-
ondary, tertiary, and, in some cases, quaternary structures, 
which are referred to as higher-order structures [34, 35]. 
Because of the relationships between structure and func-
tion, clinically meaningful differences in safety, purity, 
and/or potency may result from modifications of primary 
or higher-order structure [2]. Some biologics are glyco-
sylated. Changes in the pattern of carbohydrates attached 
to the amino acid chain (i.e., glycosylation pattern), which 
can result from production in living cells, may occur during 
manufacture based on the type of cells used to produce the 
biologic and the multistep manufacturing process. Because 
the glycosylation pattern may also contribute to the clinical 
profile of the biologic, changes in the pattern may also alter 
clinical outcomes [25, 36].
The manufacturing process for biologics is substantially 
more specialized than that for small-molecule drugs. The 
creation of a cell line used in the manufacturing of biolog-
ics involves numerous intricate processes, including iso-
lation of a targeted gene sequence, cloning of that gene 
sequence, and the use of a DNA vector to transfer the tar-
geted DNA into an expression system [33]. During produc-
tion, the cell line goes through a series of fermentation pro-
cesses. The protein of interest is then harvested, purified, 
formulated, and packaged. There is a strong relationship 
between the manufacturing processes and the characteris-
tics of the final product, which are very sensitive to produc-
tion conditions [37]. Changes or differences in manufactur-
ing processes may have a significant impact on the quality, 
purity, biologic characteristics, and clinical activity of the 
final product [26, 33, 38].
Manufacturers of biologics should have sophisticated, 
state-of-the-art manufacturing technology and quality man-
agement systems that meet all necessary regulatory require-
ments [39]. The manufacturing process for the originator 
biologic product is proprietary. Therefore, the biosimilar 
developer must analyze the reference product extensively 
and reverse engineer to produce a biologic agent that is 
highly similar to the reference product, which requires sub-
stantial knowledge, experience, and expertise regarding the 
development and manufacture of biologics.
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Comparability of biologic proteins
The inherent complexity of biologics and the intricacies of 
the manufacturing process make the final product sensitive 
to changes in production conditions. Subtle changes in, or 
differences between, manufacturing processes may result in 
significant differences that can impact quality, purity, effi-
cacy, safety, and immunogenicity [26, 38, 40].
Over time, manufacturers of originator biologics may 
implement manufacturing process changes for their mol-
ecules for reasons such as improving product stability, 
increasing the scale of production, or complying with 
changes in regulatory requirements [25, 41]. Manufacturers 
of originator products must evaluate their products pre- and 
post-manufacturing change to ensure there are no differ-
ences in efficacy or safety. In 1996, the FDA established the 
concept of “comparability” in the published guidance docu-
ment, Demonstration of Comparability of Human Biologi-
cal Products, including Therapeutic Biotechnology-derived 
Products [41]. Subsequently, this concept was included in 
the International Conference on Harmonisation (ICH) guid-
ance Q5E, Comparability of Biotechnology/Biological 
Products Subject to Changes in Their Manufacturing Pro-
cess [42]. Comparability can be based on analytical testing 
(e.g., monomer/aggregate levels, charge heterogeneity), 
in vitro biologic assays (e.g., cell-based bioassays), and/or 
non-clinical and clinical data [42, 43]. The scientific princi-
ples described in ICH Q5E also apply to the development 
of biosimilars; however, manufacturers of biosimilars use 
different cell lines, raw materials, equipment, processes, 
and process controls than the originator. Therefore, in gen-
eral, the amount of data needed to establish similarity will 
be greater than what is required to determine comparability 
following an originator’s manufacturing change [12].
Nevertheless, it is important to recognize that highly 
sophisticated analytical technologies are the basis for estab-
lishing both similarity and comparability. Biologics have 
become increasingly well characterized, and biosimilars 
are specifically engineered and designed to closely resem-
ble the originator molecule to the best extent possible using 
current technologies. Sensitive state-of-the-art orthogonal 
analytical methods are typically able to assess similarity 
with high confidence [44]. Early in product development, 
small differences (e.g., in epitope or binding characteristics 
of a biosimilar monoclonal antibody) would be identified 
from the extensive physicochemical and functional charac-
terization conducted for biosimilars.
Regulatory pathways for biosimilars
Regulatory requirements for approval of biosimilars are 
generally consistent across the EMA, Health Canada, and 
WHO, and the guidelines issued by the FDA [10–12, 45]. 
Although minor differences exist among these agency 
guidelines, with some slight differences in terminology, 
all require a stepwise approach to establish biosimilarity 
(Table 1). Biosimilars are comparable to authorized bio-
logics with demonstrated similarity to the reference prod-
uct in terms of structure, function, and biologic activity. 
These established regulatory pathways include comparative 
assessments involving analytical, non-clinical, and clini-
cal studies. Regulations require head-to-head comparative 
studies for structural characterization, functional in vitro 
assays, pharmacokinetic and pharmacodynamic evalua-
tions, and safety, efficacy, and immunogenicity assessments 
[10–12]. Biosimilarity is considered demonstrated based on 
the totality of the evidence from all evaluations, with each 
step supported by the preceding one (Fig. 1).
As a first step, analytical studies are conducted to con-
firm that the biosimilar has a foundation of quality based on 
structural and functional similarity to the reference product. 
Non-clinical studies then demonstrate that the biosimilar 
agent acts on the same target or physiologic process and 
has similar toxicity as the reference product. A crucial ele-
ment in the evaluation of a biosimilar product is a tailored 
clinical trial program that compares the pharmacokinetics, 
clinical efficacy and safety, and immunogenicity of the bio-
similar with that of the reference product.
Considerations for comparative clinical trials 
for biosimilars
Clinical development of a biosimilar necessitates a rigor-
ous head-to-head comparison with the reference product. 
The goal is to demonstrate that any difference in efficacy 
or safety between the biosimilar and reference products 
is less than a pre-specified margin of clinical equivalence 
[46]. Comparative clinical (phase III) trial designs for bio-
similars are similar to those for any biologic with respect to 
most-sensitive patient population, sample size, end points, 
and study duration (Table 2) [47]. The trials should be ran-
domized, double-blinded, and adequately powered [48].
Because the goal of a comparative clinical trial is to 
demonstrate that the proposed biosimilar is equivalent 
to the reference product, superiority trials are not appro-
priate. Instead, non-superiority trials, including equiva-
lence and non-inferiority designs, are most suitable [12]. 
Although non-inferiority trials can be used, an equivalence 
study design is preferred to demonstrate that the biosimi-
lar is equivalent to the reference product. The goal in an 
equivalence trial is to reject the null hypothesis of non-
equivalence and accept the alternative that the biosimi-
lar and reference products are equivalent. In other words, 
the trial should determine whether the biosimilar is no 
worse than and also not better than the reference product. 
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This is accomplished using a two-sided test (requiring 
superior and inferior margin limits) based on a pre-spec-
ified equivalence margin, which is selected to detect clini-
cally meaningful differences in effectiveness between the 
biosimilar and reference product at the 95 % confidence 
interval [12, 49]. In some situations, a one-sided non-
inferiority design may be appropriate if justified (e.g., if 
the original drug has a wide safety margin) [12, 48]. How-
ever, a one-sided test does not demonstrate equivalence, 
but instead demonstrates that one product is not inferior to 
another. This leaves open the possibility of a more potent 
drug, which could produce a higher number of adverse 
events; however, these studies often do not carry the statis-
tical power to demonstrate this.
Other important considerations in the design of a com-
parative clinical study between a biosimilar and reference 
product are sample size, study duration, and end points. 
Sample size is a key determining factor of the power of a 
study and may be affected by the treatment effects and the 
equivalence margins. For example, as the equivalence mar-
gins narrow, the minimum sample size increases [12]. The 
disease or condition for which the biosimilar is being stud-
ied will influence the duration of the study. When evaluat-
ing a biosimilar for RMDs, many of which are chronic, the 
comparative clinical trial should be of sufficient duration 
so that both beneficial clinical effects and potential adverse 
effects may be observed. Generally, end points are selected 
based on the end points that were used in the clinical trials 
of the reference product [12]. Furthermore, for studies in 
RMDs, end points are most often consistent with the Out-
come Measures in Rheumatology (www.omeract.org).
Evolving regulatory landscape
Regulation of biosimilar products varies among the many 
countries of Latin America. Although some countries 
in Latin America have yet to introduce guidance for bio-
similars, most are moving toward establishing standards 
of regulation for these products [50]. In recent years, 
ANMAT (Administración Nacional de Medicamentos, 
Alimentos y Tecnología Médica) in Argentina, ANVISA 
(Agência Nacional de Vigilância Sanitária) in Brazil, and 
COFEPRIS (Comisión Federal para la Protección contra 
Riesgos Sanitarios) in Mexico have developed their own 
regulatory pathways for biosimilar products by combining 
and customizing WHO and EMA guidelines for biosimi-
lars to address their regional needs [51]. In Brazil, there is 
a traditional regulatory pathway for new biologic products, 







In vivo immunogenicity, toxicity, and PK
Analytical Studies
 Structural assessments Functional assays   
Fig. 1  Biosimilar development process. Strong evidence of bio-
similarity during analytical and non-clinical studies is essential. The 
objective of a biosimilar program was to establish biosimilarity, and 
the clinical program is focused and tailored toward this objective. 
Adapted from McCamish and Woolett [41], https://creativecommons.
org/licenses/by-nc/3.0/us/legalcode
Table 2  Key considerations in evaluating comparative clinical (phase III) studies of biosimilars [47]
Comparability An equivalence design at the 90 or 95 % confidence interval is used (generally preferred to a non-inferiority design)
An equivalence design establishes that the biosimilar is neither superior nor inferior to the reference product
Patient population Should be clinically relevant
Does the study use the most sensitive patient population, that is, the population in which clinically meaningful differences 
in safety and effectiveness between the biosimilar and reference product are most likely to be detected?
Power/sample size Study is sufficiently powered to detect potential differences between biosimilar and reference product
Dose The dose and route are consistent with the reference product
End points End points are relevant to the disease state and sensitive enough to detect clinically relevant differences in efficacy and 
safety, if any, between the biosimilar and reference product
Study duration The duration of the study was appropriate to detect clinical effects
Statistical analysis A per-protocol analysis includes only patients who followed the protocol, whereas an intention-to-treat analysis includes all 
randomized patients
If the study used an equivalence design, a per-protocol analysis was used
Efficacy Are efficacy measures within the pre-specified acceptable margin of equivalence?
Safety Are the incidence and types of adverse events comparable between biosimilar and reference product?
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biologics, there are two pathways: a comparative pathway, 
which closely follows the WHO guideline, and an indi-
vidual pathway, which allows a reduced dossier presenta-
tion. Only products licensed by the comparative pathway 
are considered biosimilars [52]. The Colombian Ministry 
of Health and Social Protection (Ministerio de Salud y Pro-
tección Social de Colombia) [53] also released new draft 
guidelines for biologics, which includes biosimilars. The 
proposed draft guidelines outline three routes for registra-
tion of biologic products: a complete route, a comparabil-
ity route, and an abbreviated route, which aims to facilitate 
the registration of biosimilar products in Colombia through 
an abbreviated pathway. In addition, in Chile, Costa Rica, 
Guatemala, Panama, and Peru, recent guidelines have been 
developed based on or taking into consideration interna-
tionally accepted standards for evaluation of biosimilars 
[54].
Intended copies of biologics have been used in Latin 
American countries for many years prior to the estab-
lishment of regulatory guidelines for assessing similar-
ity between these products and their reference products. 
Intended copies of several biologics have been approved 
without quality clinical trials or adequate evaluation and 
remain on the market in some countries in Latin Amer-
ica (Table 3). For example, in Mexico, until recently, the 
approval of an intended copy of a biologic drug followed 
the same criteria as that of a generic small-molecule drug 
and preclinical and clinical data were not required. By 
2011, this policy had resulted in 23 intended copies of bio-
logics registered in Mexico as generics [18]. The Mexi-
can College of Rheumatology in 2012 published a posi-
tion paper regarding the necessary scientific evidence 
required to evaluate the efficacy and safety of biosimilar 
drugs before and after their arrival to the Mexican mar-
ket [55]. A warning to health professionals was issued by 
the Mexican Federal Commission for Protection Against 
Health Risks concerning anaphylactic reactions associ-
ated with rituximab when the originator product rituximab 
and the intended copy Kikuzubam® were interchanged 
[56]. In March 2014, a health notice was issued requiring 
the manufacturer recall all batches of Kikuzubam due to 
safety concerns and, subsequently, the product was with-
drawn from the market [57]. How to re-evaluate products 
that were previously approved but do not fit the country’s 
current regulatory criteria for a biosimilar is a significant 
global issue, especially in Latin America, as the WHO 
recent draft guidelines reflect [18, 58, 59]. It is anticipated 
that the complete assessment process for these drugs may 
be required to be completed within 2 years from the effec-
tive date of new regulation, with existing dossiers and com-
parative analytical characterization data being reviewed in 
the first 8 months. Strict adherence to the new regulation 
should be mandatory for these drugs including clinical 
studies.
A growing number of countries in Asia have established 
or are establishing regulatory pathways for evaluation and 
approval of biosimilars. Japan and South Korea released 
guidelines in 2009 [60, 61], and Singapore and Malaysia 
have generally followed EMA guidelines [62, 63]. India 
released official biosimilar guidelines in 2012 [64, 65]; 
however, these guidelines are viewed by some as less strict 
than those from the WHO, EMA, and FDA because the 
potential exists for reduced non-clinical and clinical testing 
programs if there is proof of strong quality comparability 
and manufacturing process consistency [19]. It should be 
noted that before the biosimilars regulatory pathway was 
issued in India in 2012, more than 25 products designated 
as “similar biologics” had already been approved [66]. Late 
in 2014, China’s Center for Drug Evaluation (CDE) pub-
lished draft guidance for approval of biosimilars. The new 
draft guidance outlines the principles of comparability and 
a stepwise approach to testing [67]. Previously, domestic 
“copy biologic medicines” were produced in China and 
were approved through their traditional new drug approval 
process, without comparison to the reference product.
Biosimilar naming
“Biosimilar” is a regulatory term and is distinct from nam-
ing and the WHO International Non-proprietary Name 
(INN) assignment process for biologics. Although the INN 
Table 3  Countries in which 
intended copies of listed 
biologics for rheumatic 
conditions are approved and/
or marketed without biosimilar 
regulations [14, 17, 91, 92]
a Withdrawn in 2014
Year of market introduction Rituximab Etanercept
2007 India (Reditux™) –
2008 Peru (Reditux™) Colombia (Etanar™)
2010 Chile, Bolivia (Reditux™)
Mexico (Kikuzubam®)a
–
2011 Jamaica, Ecuador (Reditux™) China (Yisaipu)
2012 Paraguay (Reditux™) Mexico (Etart™; Infitam™)
2013 – India (Etacept™)
620 Rheumatol Int (2016) 36:613–625
1 3
system, first adopted more than 50 years ago, defines global 
standards for the nomenclature of pharmaceuticals, naming 
of biosimilars is under discussion in many regions [68–70]. 
No international harmonization on biosimilar naming exists 
[71], and this creates challenges because the naming of 
biosimilars has consequences for pharmacovigilance (the 
detection, assessment, and prevention of adverse effects 
after a product is launched onto the market) [26]. Each 
biosimilar product should be easily identified and distin-
guished from the reference product and from other biosimi-
lars to ensure traceability and accurate reporting of adverse 
drug reactions [72]. Having an INN qualifier unique to the 
specific biosimilar manufacturer would be prudent from 
a traceability, pharmacovigilance, and safety perspective 
[69]. Because intended copies often have the same INNs as 
the reference products, traceability may be problematic or 
impossible.
The WHO guidelines for naming of biosimilars have 
advised that non-glycosylated biosimilars share the INN 
of the reference product, whereas glycosylated biosimilars 
should have a Greek letter suffix added to the INN. This 
approach to naming is under review, however, and the pro-
posal being considered by WHO is that all biologics (not 
just biosimilars) should have a two-part name. The first part 
would be the INN, and the second part would be a unique 
four-letter identification code (“biologic qualifier” or BQ), 
distinct from the INN, to assist in identification of biologic 
substances for prescribing, dispensing, and pharmacovigi-
lance [69].
Some countries have approved their own policies for 
biosimilar naming. According to the guidance issued by 
the Japanese regulatory Pharmaceuticals and Medical 
Devices Agency, the names of biosimilars should be eas-
ily distinguishable from those of the reference product 
and from those of other biosimilar products. Biosimilars 
are referred to by using the non-proprietary name of the 
reference product followed by the letters “BS,” in addi-
tion to the dosage form, dosage, and name of the manufac-
turer [73, 74]. Until January 2015, the naming convention 
for biosimilars followed by the Australian Department of 
Health Therapeutics Goods Administration for Australian 
Biological Names was similar to Japan’s in that it clearly 
distinguished biosimilars from reference products. Cur-
rently, however, the policy is under review in light of the 
proposed BQ system under consideration by WHO. In 
the interim, biosimilars will be identified by the Austral-
ian biologic name without a specific biosimilar identifier 
suffix [75]. The Mexican College of Rheumatology states 
that the label of each biologic product should clearly indi-
cate whether it is an innovative biologic or biosimilar 
drug [55]. In Europe, approved biosimilars share the INN 
that corresponds with that of their reference product, and 
EMA advises that the commercial name, appearance, and 
packaging should differ. In the USA, the FDA recently 
issued draft guidance on the non-proprietary naming of 
biologics [76]. The proposed naming convention applies 
to all biologics, including originator products and biosimi-
lars. Specifically, the FDA proposed that both reference 
products and biosimilars be given a four-letter suffix to 
the INN that is unique; the suffix selected will not have 
any special meaning. Although adoption of the WHO’s BQ 
system would be a voluntary decision by individual regu-
latory authorities, if widely accepted it would be a signifi-
cant step toward global harmonization. Most authorities 
agree that a distinct brand name and/or a distinct non-pro-
prietary name for a biosimilar are necessary to establish 
and maintain effective pharmacovigilance systems.
Pharmacovigilance and risk management plans
Throughout the product life cycle, the ability to moni-
tor and follow all biologics is critical to protecting patient 
safety. In order to do that, each biosimilar product should 
be readily identified and easily distinguished from the ref-
erence product and from other biosimilars. As mentioned 
above, pharmacovigilance describes the detection, assess-
ment, and prevention of adverse effects after a product 
enters the market [26]. As with all biologics, appropriate 
post-marketing pharmacovigilance will be critical to the 
appropriate use of biosimilars. In general, regulatory agen-
cies recommend that pharmacovigilance plans be devel-
oped and consider any known safety signals associated 
with the use of the reference product and its class [10–12, 
45, 63].
Recent recommendations on how to ensure the safety 
and effectiveness of biosimilars in Latin America state that 
all Latin American countries should establish a certification 
program to train pharmacovigilance experts [77]. These 
experts would manage all aspects of data collection and 
analysis related to the use and safety of pharmaceuticals. 
Any additional specific safety monitoring or pharmacovigi-
lance measures, including immunogenicity testing required 
for the reference biologic or its product class, should also 
apply to a biosimilar. In addition, any novel safety concerns 
that became apparent during evaluation of the biosimi-
lar should also be evaluated. This underscores the impor-
tance of the well-defined pathways and regulations for the 
review, approval, and pharmacovigilance of biosimilars, 
factors that may be lacking for intended copy products.
Clinical safety of biologics, including biosimilars, must 
be monitored closely on an ongoing basis during the post-
approval phase. There is a need to improve traceability, 
in particular with respect to individual batches or lots, to 
facilitate better identification and monitoring of post-
approval safety issues [78]. Physicians and other health 
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care providers need accurate data on adverse events associ-
ated with specific treatments to ensure the medicines they 
are prescribing are safe and effective. In addition, participa-
tion in registries with ongoing evaluation of safety in the 
clinical setting is often used to evaluate long-term safety. 
Registries are designed to understand the nature and fre-
quency of adverse events and potentially identify risk fac-
tors in patient populations outside clinical trials. Naming of 
biosimilars may play a major role in registries, permitting 
identification of the exact product (originator or biosimilar) 
associated with a particular adverse event.
Even with robust national reporting systems for pharma-
covigilance, a serious limitation is the extent of underreport-
ing of adverse events by health care providers. Wide varia-
tions in reporting rates of suspected adverse drug reactions 
(ADRs) have been found among countries. A survey of med-
ical practitioners in nine European countries reported that 
the percentage of respondents in each country who stated 
they had reported an ADR at least once ranged from 19.4 % 
in Italy to 74.4 % in France [79]. National reporting rates 
obtained by direct inquiry of the national regulatory authori-
ties in these countries showed a pattern similar to the individ-
ual practitioner findings (Table 4). An international system 
for monitoring ADRs was established in 1968 by WHO [80]. 
The Programme for International Drug Monitoring analyzes 
new adverse reaction signals from reports submitted by 120 
countries, and today, the database contains more than 10 mil-
lion reports of suspected ADRs [81]. Recent data collected 
worldwide indicate continuing disparity among countries in 
terms of reporting rates of ADRs. For example, among the 
20 countries with the highest rates of reporting, the rates 
range from more than 3600 reports per million inhabitants 
per year in Singapore to approximately 400 reports per mil-
lion per year in Finland (Fig. 2). Nonetheless, even in coun-
tries with high reporting rates, it has been estimated that 
fewer than 10 % of all adverse drug reactions are reported 
[82]. The success or failure of any pharmacovigilance activ-
ity depends on the timely and accurate reporting of suspected 
adverse reactions and proper traceability.
Risk management plans (RMPs) were introduced in 
2005 in Europe to support a proactive approach in gaining 
knowledge on safety concerns through early planning of 
pharmacovigilance activities, and RMPs are indispensable 
in the pharmacovigilance of new drugs [83]. The objective 
of an RMP was to protect patients from adverse events by 
ensuring that the benefits of a medicine exceed its risks by 
the greatest margin possible [84]. RMPs use scientifically 
based methodologies to identify, assess, communicate, 
and minimize risk of a drug. RMPs include information on 
a drug’s safety profile, how its risks will be prevented or 
minimized, plans for studies to increase knowledge about 
safety and efficacy, and any known risk factors for develop-
ment of adverse events. It has been recommended that the 
risk management plan for biosimilars focuses on height-
ened pharmacovigilance measures, identification of immu-
nogenicity risk, and implementation and maintenance of 
post-marketing surveillance [85].
Evidence of safety and/or efficacy issues related to the 
use of intended copies in patients with RMDs and other 
conditions has emerged in Latin America and Asia. In a 
non-comparative observational study in 110 patients with 
rheumatoid arthritis, side effects were reported in 10 % of 
patients treated with Etanar®, an intended copy of etaner-
cept marketed in Colombia [86]. Main causes of discontin-
uation of Etanar therapy were lack of efficacy, heart failure, 
nausea and dizziness, pneumonia, and asthma. In com-
parison, adverse events reported most frequently among 
patients treated with the originator etanercept include 
infections and injection site reactions [87]. In a second 
observational report of patients with rheumatic diseases 
from four hospitals in Mexico and Colombia, 10 of 14 
patients treated with Etanar or Infinitam® (another intended 
copy of etanercept) and 101 of 205 patients treated with 
Kikuzubam, an intended copy of rituximab, experienced at 
least one treatment-related adverse event [88]. Grade 3 or 
4 adverse events were experienced by 14.3 % of patients 
receiving these intended copies. Other safety issues have 
been reported with recombinant insulin in Chile and epo-
etin alpha and beta in Thailand [19]. Because of the lack of 
rigorous pharmacovigilance for these drugs, including peri-
odic safety update reports, it is difficult to know whether 
adverse events have gone undetected.
Conclusions and recommendations
Biologics are vital to the management of patients with 
RMDs such as rheumatoid arthritis and other inflammatory 
and autoimmune conditions. By providing additional treat-
ment choices, biosimilars may increase access to biologic 
Table 4  Percentages of respondents who had reported a suspected adverse drug reaction (ADR) at least once to either a national agency or 
pharmaceutical manufacturer [79]
a Reports/106 population/year
Denmark France Ireland Italy The Netherlands Portugal Spain Sweden UK
Any ADR report 66.7 74.4 53.2 19.4 33.2 48.6 44.1 65.4 62.7
National reporting ratea 295.5 389.7 318.9 44.3 76.3 8.6 120.5 347.3 340.8
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therapies, which may improve patient care. Biosimilars have 
the potential to provide savings and efficiencies for health 
care systems, which can free up resources for other impor-
tant aspects of health care. Increased access to biologics with 
the use of biosimilars must be accompanied by evidence of 
high quality and comparable safety and efficacy to the origi-
nator product. Biosimilars are developed using scientifically 
sound principles, and data requirements for the development 
and regulatory approval of biosimilars are much greater than 
those for small-molecule generic products. Intended copies 
of biologics are available in various countries, and the lack 
of information about efficacy and safety of these products 
compared with the originator biologic may put patients at 
risk. Products previously approved as intended copy biologic 
drugs should be evaluated according to the current regulations 
specific to those required for biosimilars and within a speci-
fied time period or be removed from market. High standards 
for global pharmacovigilance of non-originator biologics 
are essential and should include harmonization of biosimilar 
naming and superior systems for adverse event reporting and 
traceability of adverse events to specific products.
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